Opportunity Information: Apply for CDC RFA IP16 1607
Apply for CDC RFA IP16 1607
- The HHS-CDC-NCIRD in the health sector is offering a public funding opportunity titled "Expansion of seasonal influenza vaccination programs in low and middle income countries" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.318.
- This funding opportunity was created on Apr 22, 2016 and posted on Apr 22, 2016.
- Applicants must submit their applications by Jun 22, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $2,000,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Expansion of seasonal influenza vaccination programs in low and middle income countries" is a CDC-led cooperative agreement focused on increasing the use of seasonal influenza vaccines in low and middle income countries (LMICs), where vaccine uptake and routine influenza immunization programs have historically lagged far behind high-income settings. The underlying public health rationale is that influenza contributes to a major global disease burden each year, with an estimated 250,000 to 500,000 deaths worldwide and millions of hospitalizations. While many high-income countries have long operated annual influenza vaccination programs that prioritize people at highest risk of severe outcomes, in 2015 fewer than half of countries globally had ongoing influenza vaccine programs and only a small number of low-income countries had any such programs at all. CDC frames the expansion of seasonal influenza vaccination not only as a direct disease reduction strategy, but also as a practical step toward better pandemic preparedness, since routine immunization infrastructure and seasonal program experience can be critical when responding to a pandemic influenza event.
A central goal of the funding announcement is to broaden access to seasonal influenza vaccination in LMICs, while also generating practical evidence on what works when countries introduce or scale these programs. The opportunity emphasizes learning-by-doing: evaluating the effectiveness of vaccine introduction through a public-private partnership model and building an evidence base that can inform future global and regional decisions about influenza vaccine introduction. This aligns with CDC's Influenza Division 2015 International Program Strategic Plan, which prioritized activities intended to expand seasonal influenza vaccine use across a larger number of middle and low-income countries. In other words, the program is not just about delivering doses in the short term; it is also about documenting implementation approaches, barriers, and success factors so that countries and global stakeholders can make better-informed policy and investment decisions over time.
The program is strongly anchored in the World Health Organization's 2013 Strategic Advisory Group of Experts (SAGE) recommendations, which called for influenza vaccination of high-risk groups worldwide. SAGE identified five priority groups: children ages 6 months to 5 years, older adults, people with underlying health conditions, health care workers, and pregnant women. The policy logic is twofold: people in these groups are either more likely to suffer severe complications and death from influenza, or they are more likely to transmit influenza to individuals at high risk. The grant opportunity positions LMIC influenza vaccination programs around these priority populations, reinforcing a targeted approach that can be more feasible and impactful when resources are limited.
A key vehicle for implementation described in the announcement is the Partnership for Influenza Vaccine Introduction (PIVI), created in 2012 through collaboration among the Task Force for Global Health's Center for Vaccine Equity, CDC, and the Bill and Melinda Gates Foundation. PIVI is presented as a public-private partnership designed to help LMICs establish sustainable national seasonal influenza vaccination programs. The model includes time-limited support such as donated or discounted vaccine, necessary supplies, and technical assistance for countries that are otherwise ready to introduce or expand vaccination but lack short-term resources to do so. Importantly, the emphasis is on sustainability planning and evaluation, with the expectation that countries progressively assume financial and operational responsibility after the initial donation or external support ends. The announcement cites early PIVI experience in Lao PDR, Nicaragua, Armenia, Morocco, and Moldova, highlighting accomplishments such as progress in national policy discussions, partnerships with industry to secure free or deeply discounted vaccines, collaboration with ministries of health on program design and delivery, and early indications that countries begin taking on a larger share of program financing as the donation period concludes.
From an administrative standpoint, this is a discretionary funding opportunity offered by HHS/CDC (NCIRD) under a cooperative agreement mechanism, meaning CDC anticipates substantial involvement in the funded work rather than a hands-off grant structure. The opportunity number is CDC RFA IP16-1607 under CFDA 93.318. The anticipated scope is concentrated: CDC expected to make one award, with an award ceiling of $2,000,000. Eligibility includes nonprofit organizations with 501(c)(3) status (excluding institutions of higher education) and other eligible applicants as clarified in the full announcement. Key dates listed include an original and current closing date of June 22, 2016, with the opportunity posted and created on April 22, 2016.
Overall, the opportunity is best understood as an effort to accelerate and professionalize seasonal influenza vaccination in LMICs using a partnership-based model that combines near-term catalytic support (vaccines, supplies, technical assistance) with rigorous evaluation and sustainability planning. By focusing on WHO-defined high-risk groups and leveraging lessons from early PIVI country experiences, the program aims to reduce influenza-related illness and deaths while strengthening routine systems that also serve pandemic preparedness goals.
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The opportunity is titled "Expansion of seasonal influenza vaccination programs in low and middle income countries."
Which agency is offering this funding?
This is a discretionary funding opportunity offered by HHS/CDC, specifically within CDC's National Center for Immunization and Respiratory Diseases (NCIRD).
What type of funding mechanism is being used?
The opportunity is a cooperative agreement. That means CDC expects to have substantial involvement in the funded activities, rather than providing a hands-off award.
What is the opportunity number and CFDA number?
The opportunity number is CDC RFA IP16-1607, and the CFDA number is 93.318.
How many awards does CDC expect to make?
CDC expected to make one award.
What is the maximum funding amount (award ceiling)?
The award ceiling listed for the opportunity is $2,000,000.
Who is eligible to apply?
Eligibility includes nonprofit organizations with 501(c)(3) status (excluding institutions of higher education), along with other eligible applicants as clarified in the full announcement.
What is the main purpose of the program?
The central goal is to broaden access to seasonal influenza vaccination in low and middle income countries (LMICs) and to generate practical evidence on what works when countries introduce or scale seasonal influenza vaccination programs.
Why is CDC prioritizing seasonal influenza vaccination in LMICs?
The opportunity is based on the public health rationale that influenza contributes to a major global disease burden each year, with an estimated 250,000 to 500,000 deaths worldwide and millions of hospitalizations. CDC also frames seasonal influenza vaccination as an important step toward stronger pandemic preparedness by building routine immunization infrastructure and operational experience that can be critical during an influenza pandemic.
Is this program only about delivering vaccines?
No. The opportunity emphasizes "learning-by-doing" and building an evidence base, including documenting implementation approaches, barriers, and success factors. The program is positioned as both a disease reduction strategy and an effort to produce practical implementation evidence that can inform policy and investment decisions over time.
What implementation approach is highlighted in the announcement?
A key implementation vehicle described is the Partnership for Influenza Vaccine Introduction (PIVI), a public-private partnership model designed to help LMICs establish sustainable national seasonal influenza vaccination programs.
What is PIVI and who created it?
PIVI (the Partnership for Influenza Vaccine Introduction) was created in 2012 through collaboration among the Task Force for Global Health's Center for Vaccine Equity, CDC, and the Bill and Melinda Gates Foundation.
What kinds of support does the PIVI model provide?
The model includes time-limited support such as donated or discounted vaccine, necessary supplies, and technical assistance for countries that are ready to introduce or expand vaccination but lack short-term resources to do so.
Is the support intended to be permanent?
No. The announcement describes the support as time-limited and emphasizes sustainability planning, with an expectation that countries progressively assume financial and operational responsibility after the initial donation or external support ends.
Which populations are prioritized for vaccination under this opportunity?
The opportunity is anchored in the World Health Organization (WHO) SAGE 2013 recommendations. The five priority groups identified are: children ages 6 months to 5 years, older adults, people with underlying health conditions, health care workers, and pregnant women.
Why does the opportunity focus on these priority groups?
The policy logic described is that these groups are either more likely to suffer severe complications and death from influenza, or they are more likely to transmit influenza to individuals at high risk.
How does the opportunity describe the global gap in influenza vaccination programs?
The announcement notes that many high-income countries have long operated annual influenza vaccination programs, but that in 2015 fewer than half of countries globally had ongoing influenza vaccine programs, and only a small number of low-income countries had any such programs.
How does this work relate to CDC's broader international influenza strategy?
The opportunity aligns with CDC's Influenza Division 2015 International Program Strategic Plan, which prioritized activities intended to expand seasonal influenza vaccine use across a larger number of middle and low-income countries.
What kinds of results or learning does CDC want to generate through this program?
The announcement emphasizes evaluating the effectiveness of vaccine introduction through a public-private partnership model and building evidence on implementation, including what works, common barriers, and success factors that can inform future global and regional decisions about influenza vaccine introduction.
Which countries are mentioned as early examples of PIVI experience?
The announcement cites early PIVI experience in Lao PDR, Nicaragua, Armenia, Morocco, and Moldova.
What accomplishments are attributed to early PIVI experience in those countries?
Examples listed include progress in national policy discussions, partnerships with industry to secure free or deeply discounted vaccines, collaboration with ministries of health on program design and delivery, and early indications that countries begin taking on a larger share of program financing as the donation period concludes.
What is the closing date for this funding opportunity?
The original and current closing date listed is June 22, 2016.
When was the opportunity posted and created?
The opportunity was posted and created on April 22, 2016.
Is this opportunity specifically targeted to low and middle income countries?
Yes. The stated focus is on expanding seasonal influenza vaccination programs in LMICs, where vaccine uptake and routine influenza immunization programs have historically lagged behind high-income settings.
How does the program connect seasonal influenza vaccination to pandemic preparedness?
The opportunity describes seasonal program experience and routine immunization infrastructure as practical assets for pandemic response, since systems built for annual influenza vaccination can help countries respond more effectively during a pandemic influenza event.
Browse more opportunities from the same agency: HHS-CDC-NCIRD
Browse more opportunities from the same category: Health
Next opportunity: Program for Extramural/Intramural Alcohol Research Collaborations (U01)
Previous opportunity: Extracellular Vesicle Tools, Technologies, and Products for Neuroscience Research (R41/R42)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA IP16 1607
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA IP16 1607) also looked into and applied for these:
| Funding Opportunity |
|---|
| Program for Extramural/Intramural Alcohol Research Collaborations (U01) Apply for PAR 16 214 Funding Number: PAR 16 214 Agency: HHS-NIH11 Category: Health Funding Amount: $250,000 |
| Improving Physical Infrastructure Revisions of Center Grants (P40) Apply for RFA OD 16 010 Funding Number: RFA OD 16 010 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Support for Scale-Up of Community Package of High Impact Interventions - Phase II Apply for SOL 680 16 000007 Funding Number: SOL 680 16 000007 Agency: USAID-BEN Category: Health Funding Amount: $5,980,000 |
| Improving Physical Infrastructure to Enhance Animal Model Research: Revisions of Center Grants (P51) Apply for RFA OD 16 007 Funding Number: RFA OD 16 007 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Collaborations to Improve Identification and Care for Chronic Hepatitis B Virus (HBV) Infection among Persons in the United States who were Born in Countries with Intermediate-High (≥2%) HBV Prevalence Apply for CDC RFA PS14 141403CONT16 Funding Number: CDC RFA PS14 141403CONT16 Agency: HHS-CDC-NCHHSTP Category: Health Funding Amount: Case Dependent |
| Improving Physical Infrastructure to Enhance Animal Model Research: Revisions of Research Project Grants (R24) Apply for RFA OD 16 009 Funding Number: RFA OD 16 009 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Enhanced State Surveillance of Opioid-Involved Morbidity and Mortality Apply for CDC RFA CE16 1608 Funding Number: CDC RFA CE16 1608 Agency: HHS-CDC-NCIPC Category: Health Funding Amount: $775,000 |
| Continuing Enhanced National Surveillance for Prion Diseases in the United States Apply for CDC RFA CK12 120805CONT16 Funding Number: CDC RFA CK12 120805CONT16 Agency: HHS-CDC-NCEZID Category: Health Funding Amount: Case Dependent |
| NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22) Apply for PAR 16 220 Funding Number: PAR 16 220 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) Apply for PAR 16 219 Funding Number: PAR 16 219 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Immunization Information Systems (IIS) Capacity and Operations Support Apply for CDC RFA IP15 150102CONT16 Funding Number: CDC RFA IP15 150102CONT16 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: Case Dependent |
| Advancing the development and licensure of vaginal rings and innovative systemic methods for prevention of HIV infection in women Apply for APS OAA 16 000002 Funding Number: APS OAA 16 000002 Agency: USAID Category: Health Funding Amount: Case Dependent |
| Improving Effectiveness of the Tuberculosis Prevention and Control Programs in Resource Limited Countries Apply for CDC RFA PS14 141103CONT16 Funding Number: CDC RFA PS14 141103CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Promoting CDC's Cancer Surveillance Data Through Workforce Development and Education Apply for CDC RFA DP16 1605 Funding Number: CDC RFA DP16 1605 Agency: HHS-CDC-NCCDPHP Category: Health Funding Amount: $200,000 |
| Engaging Communities in Responding to Zika Under the Integrating Community Health APS Apply for APS OAA 15 000004 ADDENDUM2ZIKA Funding Number: APS OAA 15 000004 ADDENDUM2ZIKA Agency: USAID Category: Health Funding Amount: Case Dependent |
| PPHF 2016: Increasing HPV Vaccine Coverage by Strengthening Adolescent AFIX Activities, Financed in Part by 2016 Prevention and Public Health Funds Apply for CDC RFA IP16 1608PPHF16 Funding Number: CDC RFA IP16 1608PPHF16 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $500,000 |
| Medical Professionals Recruitment and Continuing Education Program Apply for HHS 2016 IHS HPR 0001 Funding Number: HHS 2016 IHS HPR 0001 Agency: HHS-IHS Category: Health Funding Amount: $105,000 |
| Improving Access to Care: Using Community Health Workers to Improve Linkage and Retention in HIV Care Apply for HRSA 16 185 Funding Number: HRSA 16 185 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Community Health Projects Related to Contamination at Brownfield/Land Reuse Sites Apply for CDC RFA TS16 1602 Funding Number: CDC RFA TS16 1602 Agency: HHS-CDC-ATSDR Category: Health Funding Amount: $150,000 |
| 2016 Senior Companion Program (SCP) Indian Tribes, Native Hawaiians, and Pacific Islanders Competition Apply for CNCS 05 04 2016 SCP Funding Number: CNCS 05 04 2016 SCP Agency: CNCS Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA IP16 1607", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.